NASDAQ: QNRXQuoin Pharmaceuticals Ltd Stock
$7.02+0.96 (+15.84%)
Updated Apr 2, 2026
QNRX Price
$7.02
Fair Value Price
N/A
Market Cap
$22.16M
52 Week Low
$3.33
52 Week High
$41.80
P/E
N/A
P/B
1.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.80M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.55
Operating Cash Flow
-$14M
Beta
1.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
QNRX Overview
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QNRX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
QNRX
Ranked#308 of 462
Ranked#308 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $186.95 | A | |
| $16.62 | A | |
| $22.99 | A |
Be the first to know about important QNRX news, forecast changes, insider trades & much more!
QNRX News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QNRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QNRX is good value based on its book value relative to its share price (1.69x), compared to the US Biotechnology industry average (4.77x)
P/B vs Industry Valuation
QNRX's cash and short-term investments ($18.75M) cannot cover QNRX's cash burn for the next year ($24.64M), once increasing cash burn (81.98%) is accounted for
Interest Coverage Financials
QNRX's short-term assets ($20.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more QNRX due diligence checks available for Premium users.
Valuation
QNRX fair value
Fair Value of QNRX stock based on Discounted Cash Flow (DCF)
Price
$7.02
Fair Value
$27.05
Undervalued by
74.05%
QNRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.69x
Industry
4.77x
QNRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QNRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.3M
Profit Margin
0%
QNRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$20.4M
Liabilities
$7.3M
Debt to equity
0.55
QNRX's short-term assets ($20.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QNRX's short-term assets ($20.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QNRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
QNRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.0M
Investing
-$11.3M
Financing
$18.3M
QNRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QNRX vs Biotech Stocks
Quoin Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.